← back to search

Gregory Bell

University of California, San Francisco · US
Area of research
Nephrology · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Parathyroid Disorders and Treatments, Acute Myocardial Infarction Research, Cardiac Imaging and Diagnostics, and Immune Cell Function and Interaction.
h-index
18
citations
1,611
works
33
NIH funding
primary concept
email

Recent publications

A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients
Current Medical Research and Opinion 2015cited by 40position: firstdoi
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial
European Heart Journal 2014cited by 101position: middledoi
Pharmacology of AMG 416 (Velcalcetide), a Novel Peptide Agonist of the Calcium-Sensing Receptor, for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Journal of Pharmacology and Experimental Therapeutics 2013cited by 111position: middledoi
AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients
Kidney International 2013cited by 66position: lastdoi
The Safety and Efficacy of KAI-1678— An Inhibitor of Epsilon Protein Kinase C (εPKC)—Versus Lidocaine and Placebo for the Treatment of Postherpetic Neuralgia: A Crossover Study Design
Pain Medicine 2013cited by 51position: lastdoi

Grants

Graduate Research Fellowship Program (GRFP)
NSF2439857$477,0002024–2029PIRePORTER
Graduate Research Fellowship Program (GRFP)
NSF1945980$426,0002019–2025PIRePORTER

Frequent collaborators

Saling Huang · Amgen (United States)3 papers (2013–2015)Karen Pickthorn · Amgen (United States)2 papers (2013–2013)Kévin Martin · Bridge University2 papers (2013–2015)Geoffrey A. Block · Renal Associates P. A.2 papers (2013–2015)Qun Yin · SAIC-GM (China)1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013)Felix Karim · Amgen (United States)1 papers (2013–2013)Amos Baruch · Enzo Life Sciences (United States)1 papers (2013–2013)Shawn T. Alexander · Amgen (United States)1 papers (2013–2013)David A. Power · Imperial College Healthcare NHS Trust1 papers (2013–2013)James Tomlinson · Sheffield Teaching Hospitals NHS Foundation Trust1 papers (2013–2013)Julie Janes · Dana-Farber Cancer Institute1 papers (2013–2013)Sarah Walter · University of Southern California1 papers (2013–2013)Jin Dong · AstraZeneca (Australia)1 papers (2013–2013)Dirk B. Mendel · Spark Therapeutics (United States)1 papers (2013–2013)Tom Hunter · Amgen (United States)1 papers (2013–2013)Randolph M. Johnson · Portola Pharmaceuticals (United States)1 papers (2013–2013)Derek Maclean · Southampton General Hospital1 papers (2013–2013)